Physician profile
Gaurav Jain
NPI 1649309501
$5,546.38
in general payments reported to CMS, 2019-2025
28 companies · $771 in 2025
The $771 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $564 · 2020: $456 · 2021: $230 · 2022: $1,103 · 2023: $772 · 2024: $1,651 · 2025: $771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,124 · Travel and Lodging: $56.69 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,123.76 |
| Travel and Lodging | $56.69 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $885.55 | 2019-2024 | Lokelma, Farxiga |
| Medtronic Vascular, INC. | $556.34 | 2019-2020 | |
| Amgen INC. | $409.27 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Vifor Pharma, INC. | $368.05 | 2019-2025 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $335.70 | 2019-2025 | Jynarque, Voyxact |
| Novo Nordisk INC | $325.02 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Travere Therapeutics, INC. | $322.22 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $287.42 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $248.65 | 2022-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $246.70 | 2022-2024 | Lupkynis |
| Argenx US, INC. | $220.87 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Novartis Pharmaceuticals Corporation | $188.87 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $183.28 | 2020-2025 | Terlivaz, Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.19 | 2023-2025 | Jardiance |
| Abbott Laboratories | $124.09 | 2024 | Cardiomems |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $111.76 | 2021-2023 | Onyx Frontier |
| Glaxosmithkline, LLC. | $106.03 | 2021-2024 | Benlysta, Nucala |
| Horizon Therapeutics Plc | $101.55 | 2019-2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $65.40 | 2023-2024 | Purified Cortrophin Gel |
| Opko Pharmaceuticals, LLC | $61.82 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $48.39 | 2019-2024 | Ultomiris |
| Covidien LP | $45.48 | 2019 | |
| Akebia Therapeutics INC | $27.61 | 2025 | Vafseo, Auryxia |
| Ardelyx, INC. | $22.10 | 2024 | Ibsrela |
| Lilly USA, LLC | $20.35 | 2024 | Jardiance |
| Apellis Pharmaceuticals, INC. | $20.25 | 2025 | |
| Daiichi Sankyo INC. | $19.92 | 2025 | Injectafer |
| Fresenius USA Marketing, INC. | $18.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gaurav Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.